Johnson & Johnson has secured the CE mark for ACUVUE OASYS MAX 2-Week, a reusable contact lens designed for a two-week wear cycle, marking its latest addition to the ACUVUE OASYS MAX portfolio. The product is not yet approved by the U.S. Food and Drug Administration (FDA) and remains unavailable in the United States. It is set to enter select European markets later this year, with plans for broader expansion in 2027 and 2028, contingent on local regulatory approvals and market readiness.
The lens incorporates OptiBlue Light Filter Technology, which filters at least 60% of blue-violet light, and TearStable Technology for enhanced moisture retention. It also offers Class 1 UV blocking, aligning with global standards for eye protection. Clinical trials indicate that 99% of subjects transitioned successfully from the standard ACUVUE OASYS model to ACUVUE OASYS MAX 2-Week, maintaining identical power, base curve, and diameter specifications.
Globally, around 140 million people wear contact lenses, with roughly 50% of wearers opting for reusable options—a segment Johnson & Johnson aims to address with this innovation. The company’s Jacqueline Henderson, Group Chair of Vision and MedTech, emphasized that the product is designed to meet the demands of busy lifestyles, ensuring comfort and clarity without compromises.
The rollout reflects Johnson & Johnson’s strategic focus on expanding its vision care portfolio in Europe, where demand for advanced, long-wearing contact solutions is growing. The CE mark approval underscores the product’s compliance with European safety and performance standards, positioning it for a gradual market introduction.
